Ma Jun, Liu Ting, Jin Jie, Hu Jianda, Liu Qifa, Wang Jianxiang, Shen Zhixiang, Du Xin, Jiang Bin, Meng Xianhua
Department of Hematology, Harbin Institute of Hematology & Oncology, Harbin, China.
Department of Hematology, West China Hospital of Sichuan University, Chengdu, China.
Int J Hematol Oncol. 2018 Jul 25;7(2):IJH06. doi: 10.2217/ijh-2018-0006. eCollection 2018 Jun.
Chinese adults with relapsed/refractory Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (Ph- ALL) have poor outcomes.
PATIENTS & METHODS: We conducted a nationwide, retrospective, observational study to assess outcomes in this patient population.
Of the 270 enrolled patients, 31% of patients at last salvage achieved complete remission (CR) or CR with partial hematologic recovery (CRh), with median time to CR/CRh of 30 days and median CR/CRh duration of 2.7 months. The CR/CRh rate was more favorable with earlier versus later lines of salvage (41, 24 and 17% at first, second and third or later salvages, respectively).
This dataset serves as an important reference of real-world outcomes using currently available chemotherapy regimens for high-risk Chinese adults with relapsed/refractory Ph- ALL.
复发/难治性费城染色体阴性B细胞前体急性淋巴细胞白血病（Ph-ALL）的中国成年患者预后较差。
我们开展了一项全国性的回顾性观察研究，以评估该患者群体的预后。
在270例入组患者中，末次挽救治疗时31%的患者达到完全缓解（CR）或伴有部分血液学恢复的CR（CRh），达到CR/CRh的中位时间为30天，CR/CRh的中位持续时间为2.7个月。挽救治疗线数较早者的CR/CRh率优于较晚者（首次、第二次及第三次或更晚挽救治疗时分别为41%、24%和17%）。
该数据集为使用当前可用化疗方案治疗复发/难治性Ph-ALL高危中国成年患者的真实世界预后提供了重要参考。
